Major publications

1. Geoerger B, Kang HJ, Yalon-Oren M, Marshall LV, Vezina C, Pappo A, Laetsch TW, Petrilli AS, Handgretinger R, Toporski J, Glade-Bender J, Nicholls W, Fox E, DuBois SG, Macy M, Cohn S, Pathiraja K, Diede S, Ebbinghaus S, Pinto N. Phase 1/2 KEYNOTE-051 study of pembrolizumab in pediatric patients with advanced melanoma or a PD-L1+ advanced, relapsed or refractory solid tumor or lymphoma. Lancet Oncol. 2020 Jan;21(1):121-133. doi: 10.1016/S1470-2045(19)30671-0. PMID:31812554

Pediatric Precision Medicine and Experimental Therapeutics

This group belongs to the UMR 1015 "Tumour Immunology and anti-cancer immunotherapy".

The aim of our group is to develop new innovative therapies for children with advanced cancers through our clinical precision cancer medicine trials, with one group focusing on osteosarcoma classification and development of new innovative adapted therapies in children, adolescent and young adults.

Lab members

• Nazanine Modjtahedi, DR2, CNRS, team leader
• Lluis M Mir, DRCE, CNRS
• Catherine Brenner, DR2, CNRS
• Franck M André, CRCN, CNRS
• Giorgia Urbinati, CRCN, CNRS
• Jean-Remi Bertrand, IR, INSERM
• Alain Deroussent, IR, CNRS
• Céline Gracia, IE, CNRS
• Dawei Liu, Post-doc, INCA/CNRS
• Camille Reinhardt, Post-doc, INCA/CNRS
• Thai -Hoa Chung, Doc, Université Paris-Saclay
• Amina Ghorbel, Doc, Université Paris-Saclay
• Kenza Nedara, Doc, Université Paris-Saclay

Major publications

• Reinhardt C, Arena G, Nedara K, Edwards R, Brenner C, Tokatlidis K, Modjtahedi N. AIF meets the CHCHD4/Mia40-dependnet mitochondrial import pathway. Biochim Biophys Acta Mol Basis Dis. 2020 Jun 1;1866(6):165746. doi: 10.1016/j.bbadis.2020.165746.
• Pervaiz S, Bellot G, Lemoine A, and Brenner C. Redox Signaling in the pathogenesis of human disease and the regulatory role of autophagy. Int Rev Cell Mol Biol. 2020, in press.

Metabolic plasticity in health and disease

This group belongs to the UMR 9018 - Metabolic and systemic aspects of oncogenesis for novel therapeutic approaches (Metsy)

DNA repair, chromatin remodeling and epigenetics
Lab members

• Roman Chabanon, post-doctorant
• Thomas Eychenne, post-doctorant
• Daphné Morel, Doctorante
• Clémence Hénon, Doctorante
• Carine Ngo, Doctorante,
• Asuka Kawai-Kawachi, ESMO Fellow
• Marlène Garrido, Ingénieure
• Nicolas Dorvault, Technicien
• Léo Colmet-Daage, bioinformaticien

DNA repair, chromatin remodeling and epigenetics
Major publications

1. Epigenetic drugs in solid tumours: lessons learned and future promises? Morel D, Jeffery D, Aspeslagh S, Almouzni G, Postel-Vinay S. Nature Reviews Clinical Oncology 2019 Sep 30. doi: 10.1038/s41571-019-0267-4 [Epub ahead of print]

DNA repair, chromatin remodeling and epigenetics

This team belongs to the UMR 981 - Molecular predictors and new targets in oncology.

Major publications

1: Dercle L, Ammari S, Roblin E, Bigorgne A, Champiat S, Taihi L, Plaian A, Hans S, Lakiss S, Tselikas L, Rouanne M, Deutsch E, Schwartz LH, Gönen M, Flynn J, Massard C, Soria JC, Robert C, Marabelle A. High serum LDH and liver metastases are the dominant predictors of primary cancer resistance to anti-PD(L)1 immunotherapy. Eur J Cancer. 2022 Dec;177:80-93. doi: 10.1016/j.ejca.2022.08.034. Epub 2022 Sep 30. PMID: 36332438.